This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jul;96(7):1046.

doi: 10.1136/bjophthalmol-2011-301241. Epub 2011 Nov 28.

5.7 Times more expensive than liquid gold

Gordon S Bowler, Tessa Fayers, Pieter Gouws

PMID: 22128103
DOI: 10.1136/bjophthalmol-2011-301241

Comment

5.7 Times more expensive than liquid gold

Gordon S Bowler et al. Br J Ophthalmol. 2012 Jul.

. 2012 Jul;96(7):1046.

doi: 10.1136/bjophthalmol-2011-301241. Epub 2011 Nov 28.

Authors

Gordon S Bowler, Tessa Fayers, Pieter Gouws

PMID: 22128103
DOI: 10.1136/bjophthalmol-2011-301241

No abstract available

PubMed Disclaimer

Comment on

Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review.
Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M. Schmucker C, et al. Br J Ophthalmol. 2011 Mar;95(3):308-17. doi: 10.1136/bjo.2009.178574. Epub 2010 Oct 22. Br J Ophthalmol. 2011. PMID: 20971791

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information